Medical Independent: New molecular technology required for SCID and SMA screening – HSE
The introduction of new molecular technology to the National Newborn Bloodspot Screening Laboratory (NNBSL) is required to implement screening for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA), according to the HSE. The Executive indicated this was an additional requirement to the “substantial” body of work required to introduce any new condition to the programme.
Expansion of heel prick test could save or improve the lives of 200 babies born each year in Ireland.
MDI joined with other members of Rare Diseases Ireland outside the Dáil to launch a new Get Rare Aware campaign calling for the number of conditions newborn babies are screened for under the HSE National Newborn Bloodspot Screening Programme, more commonly known as the heel prick test, to be expanded from the current nine to the European average of 18 minimum. Support the campaign by contacting your Oireachtas representatives and ask them to demand that Ireland is above average when it comes to newborn screening.